Literature DB >> 2770435

Influence of HDV infection on clinical, biochemical and histological presentation of HBsAg positive chronic hepatitis.

E Sagnelli1, F M Felaco, P Filippini, G Pasquale, P Peinetti, E Buonagurio, L Aprea, C Pulella, F Piccinino, G Giusti.   

Abstract

In an attempt to identify some characteristics of HDV infection in the different forms of HBsAg positive chronic hepatitis (CH), we evaluated numerous clinical, biochemical and histological aspects in 203 consecutive HBsAg positive CH patients. The presence of hepatitis delta antigen (HD-Ag) in the liver tissue was the criterion used to identify HDV infection. HD-Ag was observed in none of the 7 patients with non-specific reactive hepatitis, in 14.6% of the 48 with chronic persistent hepatitis (CPH), in 36.4% of the 44 with chronic lobular hepatitis (CLH), in 36% of the 25 with mild chronic active hepatitis (CAH), in 52% of the 36 with severe CAH and in 30.2% of the 43 with inactive or moderately active cirrhosis. Compared with the 139 HD-Ag negative patients in this study, the 64 HD-Ag positive patients more frequently had severe CAH (29.7 vs. 12.2%, p less than 0.01) and less frequently CPH (10.9 vs. 29.5%, p less than 0.01). Of the 139 HD-Ag negative patients, 80 were anti-HD positive and 59 anti-HD negative. The 59 patients with no HD-Ag or anti-HD showed severe CAH less frequently than the 64 HD-Ag positive patients (6.8 vs. 29.7, p less than 0.01) and CPH more frequently (44.1 vs. 10.9, p less than 0.001). Both in CPH and CLH the presence of HD-Ag in the hepatocytes identified subgroups of patients who frequently showed high serum levels of aminotransferases and gammaglobulins and more extended areas of circumscribed lobular necrosis. HD-Ag positive CAH was characterized by a more frequent occurrence of eosinophilic degeneration of hepatocytes without peripolesis (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2770435     DOI: 10.1111/j.1600-0676.1989.tb00404.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  6 in total

1.  Interaction between HDV and HBV infection in HBsAg-chronic carriers.

Authors:  E Sagnelli; F M Felaco; M Rapicetta; T Stroffolini; A Petruzziello; T Annella; P Chionne; G Pasquale; P Filippini; P Peinetti
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

2.  Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep).

Authors:  G Fattovich; G Giustina; E Christensen; M Pantalena; I Zagni; G Realdi; S W Schalm
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

Review 3.  Delta hepatitis: molecular biology and clinical and epidemiological features.

Authors:  L B Polish; M Gallagher; H A Fields; S C Hadler
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

Review 4.  Pathogenesis of and New Therapies for Hepatitis D.

Authors:  Christopher Koh; Theo Heller; Jeffrey S Glenn
Journal:  Gastroenterology       Date:  2018-10-18       Impact factor: 22.682

5.  Development and evaluation of a baseline-event-anticipation score for hepatitis delta.

Authors:  B Calle Serrano; A Großhennig; M Homs; B Heidrich; A Erhardt; K Deterding; J Jaroszewicz; B Bremer; A Koch; M Cornberg; M P Manns; M Buti; H Wedemeyer
Journal:  J Viral Hepat       Date:  2014-03-27       Impact factor: 3.728

6.  Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology.

Authors:  James Neuberger; Jai Patel; Helen Caldwell; Susan Davies; Vanessa Hebditch; Coral Hollywood; Stefan Hubscher; Salil Karkhanis; Will Lester; Nicholas Roslund; Rebecca West; Judith I Wyatt; Mathis Heydtmann
Journal:  Gut       Date:  2020-05-28       Impact factor: 23.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.